What is known and objective: Impetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children. Antibiotics are the first-line treatment when multiple lesions exist, but with an increasing prevalence of antibioticresistant bacteria the successful management of impetigo in the future is an area of concern.
| WHAT IS KNOWN AND OBJECTIVE
Impetigo is a highly contagious bacterial skin infection with a substantial disease burden. 1 It overwhelmingly affects children and is the most common bacterial skin infection in young children aged between 2 and 5 years. 1, 2 Adults may also be vulnerable to infection in certain environments, such as when living, working or engaging in recreational activity that requires close proximity. 3, 4 The incidence is highest in tropical and subtropical climates, particularly within resource-poor communities, where inadequate housing and poor hygiene contribute to the growing impact of the disease. 1, 5 Globally, the number of children suffering from impetigo at any one time is in excess of 162 million. 1 In Australia, it is estimated that over 15 000 Indigenous children suffer from impetigo at any one time. 1 Historically, impetigo has been considered a mild childhood skin infection, but it has the potential to result in more severe infections, including acute rheumatic fever (ARF) and rheumatic heart disease (RHD). The incidence of ARF and RHD is considerably greater among Indigenous populations and disadvantaged groups, where impetigo is highly prevalent. 1, 5, 6 There are two common forms of impetigo: non-bullous and bullous; the cause and clinical appearance of each are distinct. Non-bullous
impetigo comprises approximately 70% of all cases and is caused by
Staphylococcus aureus or S. pyogenes. 7 Clinically, non-bullous impetigo is characterized by the presence of small pustules, which quickly develop yellowish-brown crusted plaques. 8 Lesions are generally located on the face and extremities and often appear in already traumatized skin, such as on an existing abrasion, insect bite or eczema. 8 Bullous impetigo is caused by S. aureus and usually takes the appearance of large bullae, which tend to be located in intertriginous areas of the body. 7 In a Cochrane review, the use of topical and oral antibiotics was considered efficacious in the treatment of non-bullous and bullous impetigo. 9 However, in the past decade there has been a rise in the prevalence of antibiotic-resistant bacteria and the continued treatment of some infections using current antibiotics is an area of increasing concern. 10 
| COMMENT
Impetigo is generally considered a self-limiting condition; it is likely to resolve without intervention in a period of up to 4 weeks. 7 However, the lesions present during an infection are highly contagious and contribute to considerable disability and social stigma.
Impetigo may lead to secondary infection and, in rare cases, to the development of more serious conditions. Hence, treatment is recommended. Currently, topical mupirocin is typically the first-line therapy, whereas patients with numerous lesions or who fail to respond to topical treatment should be treated with an oral antibiotic, with options including dicloxacillin, amoxicillin/clavulanate and cephalexin.
12-14
Mupirocin (pseudomonic acid A) is the major metabolite of Pseudomonas fluorescens fermentation. 14 It acts by inhibiting bac- 14 Adverse reactions are reported in 3% of patients, with itching and irritation at the application site being most common. 14 In remote Indigenous communities in central and northern Australia, S. pyogenes is usually the pathogen, 15 and the recommended therapy is either benzathine penicillin (single dose intramuscularly) or trimethoprim plus sulfamethoxazole.
13,16
The 2012 Cochrane review of the effectiveness of interventions for impetigo examined the results of 24 randomized control trials and revealed several effective treatments. 9 Two of the most widely used topical treatments for impetigo at the time of review, fusidic acid and mupirocin, were identified as equally effective at reducing the severity of infection and time to recovery. 9 The use of oral antibiotics, typically reserved for moderate or severe cases, 12, 13, 17 or where resistance to topical treatment has been observed, also demonstrated effectiveness; but oral antibiotics were identified as inferior when compared to topical treatment using fusidic acid or mupirocin. Retapamulin (Altabax, GlaxoSmithKline; pleuromutilin class antibiotic) 1% ointment is another topical antibiotic listed for use in children older than 9 months and adults with impetigo caused by methicillinsusceptible S. aureus and S. pyogenes. It appears to have similar efficacy to fusidic acid. 9 Its bacteriostatic action is similar to that of macrolides and clindamycin. 18 However, drug resistance to retapamulin is considered unlikely because of its unique mode of action.
19
Many of the studies in the Cochrane review examined topical and oral antibiotics, with a notable lack of studies examining antimicrobials and antiseptics. 20 There is limited evidence for the efficacy of topical antiseptics, such as hydrogen peroxide, compared to topical antibiotics. 21 However, although topical antimicrobials may provide potentially attractive alternatives to antibiotics, and there is substantial anecdotal evidence supporting their efficacy, the objective evidence at present is insufficient to support their routine use for treatment over topical antibiotics. The scarcity of rigorous data related to use of topical antiseptics and antimicrobials is problematic and is worthy of additional research attention. The use of alternative treatments, such as tea tree oil, also shows promise 22 and has been proposed as a treatment for scabies. 23 However, additional studies are necessary to improve the evidence base for its use. An upcoming randomized controlled trial comparing topical hydrogen peroxide cream, topical fusidic acid or wound management only (clean and cover) will help provide evidence about the effectiveness of alternative treatments. 24 The absence of sufficient studies and high-quality evidence for the use of new or alternative treatments for impetigo may be due, in part, to the ethical and research challenges associated with investigating the treatment of paediatric and disadvantaged populations.
The increasing prevalence of antibiotic-resistant bacteria has led
to concerns about the continued use of both topical and oral antibiotics for the treatment of impetigo. 10, 25 The World Health Organization (WHO) report on Antimicrobial Resistance (AMR) in 2014 11 identified a significant need to prioritize the management of AMR. Globally, AMR is considered a major threat to public health and endangers the continued efforts to prevent and treat infectious disease in both poorly developed and highly developed nations. 11 Moreover, the report identified an increase in healthcare expenditure due to AMR associated with the cost of new drugs, longer hospital admissions and increased morbidity and mortality. 11 The increase in the development of antibiotic-resistant bacteria has been observed in communities, hospitals and primary care settings. 26 Methicillin-resistant S. aureus (MRSA) is increasingly identified in community settings, where it was once confined to healthcare facilities.
11
The increase in AMR also leads to questions surrounding the current efficacy of impetigo treatments that were included in the Cochrane review and other literature, as the studies could not account for changes in bacterial resistance in recent years. Most studies were conducted over a decade ago, when the prevalence of AMR was considerably lower. 20 Treatments such as penicillin V, once effective for impetigo, are no longer effective, whereas resistance to macrolides is also now common. 9 There is also evidence of resistance against cloxacillin, clindamycin, cephalexin and, most recently, mupirocin.
14,19
Treatment of impetigo due to MRSA requires second-line antibiotics, which are costlier and have an increased range of side effects.
11
Bacterial resistance to fusidic acid 10, 14, [27] [28] [29] [30] and mupirocin 14, 19, 31 has heightened concerns about the high rates of topical use of antibiotics. Howden 32 cautioned against their first-line use for impetigo and argued that agents that are effective when used orally should not also be widely used as a topical agent and that to lose such an agent due to widespread use would be "dumb." 32 The challenge remains in successfully treating impetigo while maintaining the efficacy of agents like fusidic acid.
Bacterial resistance is constantly evolving, and patterns of resistance vary between settings and geographical locations. Hence, it is important that prescribers are aware of location-specific data on resistance patterns in order to ensure appropriate prescribing practices. 19, 20 Practice recommendations suggest that prescribers continually monitor the expression of bacteria within their communities to inform treatment selection. 33 A study of prescribing practices in the Kimberley, a remote region in Australia with a very high incidence of impetigo, found that primary care physicians were often using secondline treatments for impetigo in an attempt to improve efficacy. 33 However, as a result, it was established that these practices were inconsistent with the principles of preventing AMR, and guidelines were subsequently revised for the management of impetigo. 33 The use of antibiotics is also associated with potential adverse 
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